Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Everolimus in Liver Transplant
NCT01150097Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of everolimus in Liver transplant rejection (3 arms), sponsored by Novartis. Primary endpoints: Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR), Graft Loss or Death and Change in Renal Function. Started Mar 2010; status: completed.
02
Drugs
everolimus
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT01150097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01150097.